Antifungal  	Antifungal  	 JJ	B-NP
drug  	drug  	 NN	I-NP
resistance 	resistance 	 NN	I-NP
:  	:  	 :	O
mechanisms 	mechanisms 	 NNS	O
,  	,  	 ,	O
epidemiology 	epidemiology 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
consequences  	consequences  	 NNS	B-NP
for  	for  	 IN	I-NP
treatment  	treatment  	 NN	I-NP
Antifungal  	Antifungal  	 NNP	I-NP
resistance  	resistance  	 NN	I-NP
continues  	continues  	 VBZ	O
to  	to  	 TO	O
grow  	grow  	 VB	O
and  	and  	 CC	O
evolve  	evolve  	 VB	O
and  	and  	 CC	O
complicate  	complicate  	 VB	O
patient  	patient  	 JJ	O
management 	management 	 NN	O
,  	,  	 ,	O
despite  	despite  	 IN	O
the  	the  	 DT	O
introduction  	introduction  	 NN	B-NP
of  	of  	 IN	O
new  	new  	 JJ	O
antifungal  	antifungal  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
vitro  	vitro  	 JJ	B-NP
susceptibility  	susceptibility  	 JJ	I-NP
testing  	testing  	 NN	I-NP
is  	is  	 VBZ	O
often  	often  	 RB	O
used  	used  	 VBN	O
to  	to  	 TO	O
select  	select  	 VB	O
agents  	agents  	 NNS	O
with  	with  	 IN	O
likely  	likely  	 JJ	O
activity  	activity  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
given  	given  	 VBN	O
infection 	infection 	 NN	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
perhaps  	perhaps  	 RB	O
its  	its  	 PRP$	O
most  	most  	 RBS	O
important  	important  	 JJ	O
use  	use  	 NN	O
is  	is  	 VBZ	O
in  	in  	 IN	O
identifying  	identifying  	 VBG	B-NP
agents  	agents  	 NNS	I-NP
that  	that  	 WDT	O
will  	will  	 MD	O
not  	not  	 RB	O
work 	work 	 VB	O
,  	,  	 ,	O
i.e. 	i.e. 	 FW	O
,  	,  	 ,	O
to  	to  	 TO	O
detect  	detect  	 VB	O
resistance 	resistance 	 NN	O
.  	.  	 .	O
Standardized  	Standardized  	 JJ	B-NP
methods  	methods  	 NNS	I-NP
for  	for  	 IN	O
reliable  	reliable  	 JJ	O
in  	in  	 IN	O
vitro  	vitro  	 JJ	B-NP
antifungal  	antifungal  	 JJ	I-NP
susceptibility  	susceptibility  	 JJ	I-NP
testing  	testing  	 NN	I-NP
are  	are  	 VBP	O
now  	now  	 RB	O
available  	available  	 JJ	O
from  	from  	 IN	O
the  	the  	 DT	O
Clinical  	Clinical  	 NNP	O
and  	and  	 CC	O
Laboratory  	Laboratory  	 NNP	B-NP
Standards  	Standards  	 NNPS	I-NP
Institute  	Institute  	 NNP	O
( 	( 	 -LRB-	O
CLSI 	CLSI 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
United  	United  	 NNP	B-NP
States  	States  	 NNPS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
European  	European  	 NNP	B-NP
Committee  	Committee  	 NNP	I-NP
on  	on  	 IN	I-NP
Antimicrobial  	Antimicrobial  	 NNP	I-NP
Susceptibility  	Susceptibility  	 NNP	I-NP
Testing  	Testing  	 NNP	I-NP
( 	( 	 -LRB-	O
EUCAST 	EUCAST 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
Europe 	Europe 	 NNP	O
.  	.  	 .	O
Data  	Data  	 NNP	O
gathered  	gathered  	 VBD	O
by  	by  	 IN	O
these  	these  	 DT	O
standardized  	standardized  	 JJ	O
tests  	tests  	 NNS	O
are  	are  	 VBP	O
useful  	useful  	 JJ	O
( 	( 	 -LRB-	O
in  	in  	 IN	O
conjunction  	conjunction  	 NN	O
with  	with  	 IN	O
other  	other  	 JJ	O
forms  	forms  	 NNS	O
of  	of  	 IN	O
data 	data 	 NNS	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
calculating  	calculating  	 VBG	O
clinical  	clinical  	 JJ	B-NP
breakpoints  	breakpoints  	 NN	I-NP
and  	and  	 CC	O
epidemiologic  	epidemiologic  	 JJ	B-NP
cutoff  	cutoff  	 NN	I-NP
values  	values  	 NNS	I-NP
( 	( 	 -LRB-	O
ECVs 	ECVs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Clinical  	Clinical  	 JJ	B-NP
breakpoints  	breakpoints  	 NN	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
selected  	selected  	 VBN	O
to  	to  	 TO	O
optimize  	optimize  	 VB	O
detection  	detection  	 VBN	O
of  	of  	 IN	O
non-wild-type  	non-wild-type  	 NNP	B-NP
( 	( 	 -LRB-	O
WT 	WT 	 NNP	B-NP
)  	)  	 -RRB-	O
strains  	strains  	 NNS	O
of  	of  	 IN	O
pathogens 	pathogens 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
they  	they  	 PRP	O
should  	should  	 MD	O
be  	be  	 VB	O
species-specific  	species-specific  	 JJ	B-NP
and  	and  	 CC	O
not  	not  	 RB	O
divide  	divide  	 VBP	O
WT  	WT  	 JJ	B-NP
distributions  	distributions  	 NNS	I-NP
of  	of  	 IN	O
important  	important  	 JJ	O
target  	target  	 NN	B-NP
species 	species 	 NNS	I-NP
.  	.  	 .	O
ECVs  	ECVs  	 NNS	B-NP
are  	are  	 VBP	O
the  	the  	 DT	O
most  	most  	 RBS	O
sensitive  	sensitive  	 JJ	B-NP
means  	means  	 NNS	I-NP
of  	of  	 IN	I-NP
identifying  	identifying  	 VBG	I-NP
strains  	strains  	 NNS	I-NP
with  	with  	 IN	O
acquired  	acquired  	 JJ	O
resistance  	resistance  	 NN	B-NP
mechanisms 	mechanisms 	 NNS	I-NP
.  	.  	 .	O
Various  	Various  	 JJ	B-NP
mechanisms  	mechanisms  	 NNS	I-NP
can  	can  	 MD	O
lead  	lead  	 VB	O
to  	to  	 TO	O
acquired  	acquired  	 JJ	O
resistance  	resistance  	 NN	O
of  	of  	 IN	O
Candida  	Candida  	 NNP	B-NP
species  	species  	 NNS	I-NP
to  	to  	 TO	O
azole  	azole  	 VB	O
drugs 	drugs 	 NNS	O
,  	,  	 ,	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
being  	being  	 VBG	B-NP
induction  	induction  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
efflux  	efflux  	 JJ	I-NP
pumps  	pumps  	 NNS	O
encoded  	encoded  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
MDR  	MDR  	 NNP	B-NP
or  	or  	 CC	O
CDR  	CDR  	 NNP	B-NP
genes 	genes 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
acquisition  	acquisition  	 NN	O
of  	of  	 IN	O
point  	point  	 NN	B-NP
mutations  	mutations  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
gene  	gene  	 NN	B-NP
encoding  	encoding  	 NN	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
target  	target  	 NN	I-NP
enzyme  	enzyme  	 NNS	I-NP
( 	( 	 -LRB-	O
ERG11 	ERG11 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Acquired  	Acquired  	 VBN	B-NP
resistance  	resistance  	 NN	I-NP
of  	of  	 IN	I-NP
Candida  	Candida  	 NNP	I-NP
species  	species  	 NNS	I-NP
to  	to  	 TO	O
echinocandins  	echinocandins  	 NN	B-NP
is  	is  	 VBZ	O
typically  	typically  	 RB	O
mediated  	mediated  	 VBN	O
via  	via  	 IN	O
acquisition  	acquisition  	 NN	O
of  	of  	 IN	O
point  	point  	 NN	B-NP
mutations  	mutations  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
FKS  	FKS  	 NNP	B-NP
genes  	genes  	 NNS	O
encoding  	encoding  	 VBP	O
the  	the  	 DT	O
major  	major  	 JJ	O
subunit  	subunit  	 NN	B-NP
of  	of  	 IN	O
its  	its  	 PRP$	O
target  	target  	 NN	B-NP
enzyme 	enzyme 	 NN	I-NP
.  	.  	 .	O
Antifungal  	Antifungal  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
elevated  	elevated  	 JJ	O
minimum  	minimum  	 JJ	O
inhibitory  	inhibitory  	 JJ	B-NP
concentrations 	concentrations 	 NNS	I-NP
,  	,  	 ,	O
poorer  	poorer  	 JJR	O
clinical  	clinical  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
breakthrough  	breakthrough  	 NN	B-NP
infections  	infections  	 NNS	I-NP
during  	during  	 IN	O
antifungal  	antifungal  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
and  	and  	 CC	O
prophylaxis 	prophylaxis 	 NN	B-NP
.  	.  	 .	O
Candidemia  	Candidemia  	 JJ	O
due  	due  	 JJ	O
to  	to  	 TO	O
Candida  	Candida  	 NNP	B-NP
glabrata  	glabrata  	 NN	I-NP
is  	is  	 VBZ	O
becoming  	becoming  	 VBG	O
increasingly  	increasingly  	 RB	O
common 	common 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
C  	C  	 $	O
glabrata  	glabrata  	 CD	B-NP
isolates  	isolates  	 NNS	O
are  	are  	 VBP	O
increasingly  	increasingly  	 RB	O
resistant  	resistant  	 JJ	O
to  	to  	 TO	O
both  	both  	 DT	O
azole  	azole  	 NN	B-NP
and  	and  	 CC	O
echinocandin  	echinocandin  	 JJ	B-NP
antifungal  	antifungal  	 JJ	I-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
situation  	situation  	 NN	O
requires  	requires  	 VBZ	O
continuing  	continuing  	 VBG	B-NP
attention 	attention 	 NN	I-NP
.  	.  	 .	O
Rates  	Rates  	 NNS	O
of  	of  	 IN	O
azole-resistant  	azole-resistant  	 NNP	B-NP
Aspergillus  	Aspergillus  	 NNP	I-NP
fumigatus  	fumigatus  	 NNS	I-NP
are  	are  	 VBP	O
currently  	currently  	 RB	O
low 	low 	 JJ	O
,  	,  	 ,	O
but  	but  	 CC	O
there  	there  	 EX	O
are  	are  	 VBP	O
reports  	reports  	 NNS	O
of  	of  	 IN	O
emerging  	emerging  	 VBG	B-NP
resistance 	resistance 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
multi-azole  	multi-azole  	 JJ	I-NP
resistant  	resistant  	 JJ	O
isolates  	isolates  	 NN	O
in  	in  	 IN	O
parts  	parts  	 NNS	O
of  	of  	 IN	O
Europe 	Europe 	 NNP	O
.  	.  	 .	O
